## New Brief Pulse ECT with Computer-Assisted Easy Seizure Monitoring



- Automatically monitors your choice of EEG-EEG, EEG-ECG, or EEG-EMG and determines EEG and motor seizure lengths.
- Computer-measured seizure quality, including postictal EEG suppression, seizure energy index.
- Up to 8 seconds stimulus duration; pulsewidth as short as 0.5 ms.
- Single dial sets stimulus charge by age; high-dose option available.
- FlexDial<sup>™</sup> adjusts pulsewidth and frequency without altering dose.

Distributed in the U.K. by: Distributed in Australia by: Distributed in New Zealand by: **DANTEC Electronics, Ltd. MEECO Holdings Pty. Ltd.** WATSON VICTOR, Ltd. **Garonor Way** 10 Seville St. 4 Adelaide Rd. Royal Portbury North Parramatta NSW 2151 Wellington, New Zealand **Bristol BS20 9XE** Australia TEL (64) 4-385-7699 TEL (44) 1275-375333 TEL (61) 2630-7755 FAX (64) 4-384-4651 FAX (44) 1275-375336 FAX (61) 2630-7365

Distributed in India by: Distributed in Pakistan by: Distributed in South Africa by:

DIAGNO.SYS IQBAL & CO. DELTA SURGICAL
New Delhi Islamabad Craighall

 New Delhi
 Islamabad
 Craighall

 TEL (91) 11-644-0546
 TEL (92) 51-291078
 TEL (27) 11-792-6120


 FAX (91) 11-622-9229
 FAX (92) 51-281623
 FAX (27) 11-792-6926

Distributed in U.S.A. and Canada by:

SOMATICS, INC., 910 Sherwood Drive # 17, Lake Bluff, IL, 60044, U.S.A. Fax: (847) 234-6763; Tel: (847) 234-6761

## REASON TO BE CHEERFUL







Abbreviated Prescribing Information: LUSTRAL™ (sertraline) Presentation: Tablets containing 50mg or 100mg sertraline. Indications: Treatment of symptoms of depressive illness and accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes including accompanying symptoms of anxiety.

Dosage: LUSTRAL should be given as a single daily dose. The initial dose is 50mg

and the usual therapeutic dose is 50mg daily. Dosage can be further increased, if appropriate, to 150mg or a maximum of 200mg daily. Patients should be maintained on the lowest effective dose and doses of 150mg or more should not be used for periods exceeding 8 weeks. Use in children: Not recommended. Use in the elderly: Usual adult dose. Contra-indications:

Hypersensitivity to LUSTRAL. Hepatic insufficiency. Use during hypersensimity to LOSI HAL. Ineplate institutionerly. Use during pregnancy: LUSTRAL should be used only if clearly needed. Lactation: Not recommended. Precautions, warnings: Renal insufficiency, unstable epileps, ECT, driving, LUSTRAL should be discontinued in a patient who develops seizures. LUSTRAL should not be administered to patients concurrently being treated with tranquillizers who drive or operate. machinery. Do not use with, or within two weeks of ending treatment with, MAOIs. At least 14 days should elapse before starting any MAOI following discontinuation of LUSTRAL. Patients should be closely supervised for the possibility of suicide attempt or activation of maniahypomania. Drug interactions: Administer with caution in combination with other centrally active medication. Serotonergic drugs including tryptophan, sumatriptan and fenfluramine should not be used with LUSTRAL. It is recommended that plasma lithium levels be monitored following initiation of LUSTRAL. Although LUSTRAL has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for LUSTRAL to interact with other highly protein bound drugs should be borne in mind. The potential of LUSTRAL to interact with e.g. warfarin, diazepam tobutamide and cimetitine has not been fully assessed. With warfarin profirmide time should be monitored when LUSTRAL is initiated or stopped. Side-effects: Dry mouth, nausea, diarrhoea/loose stools. ejaculatory delay, tremor, increased sweating, dyspepsia, dizziness, insomnia and somnolence. Asymptomatic elevations in serum transaminases have been reported infrequently (approx. 0.8%) in association with LUSTRAL. These usually occurred within the first 9 weeks association with LDS I PML. Tress usually occurred within the thirst is week treatment and resolved on cessation of therapy. Malaise and rash have been reported. Seizures (see precautions, warnings). There have been isolated reports of movement disorders and rare cases of hyponatraemia. Legal category: POM. Basic NHS cost: 50mg tablet (PL 57/3038) Calendar pack of 28, £26.51; 100mg tablet (PL 57/3039) Calendar pack of 28, £39.77. Further information on request.

Invicta™ Pharmaceuticals or Richborough™ Pharmaceuticals Richborough™ Pharmaceuticals
Divisions of Pfizer Limited, Sandwich, Kent.

RICHBOROUGH



